(주)킴앤프렌즈
Description: Charles River acquires Vigene Biosciences, a trusted leader in contract development and manufacturing solutions for gene therapy.
manufacturing (3565) cdmo (138) cell therapy (66) gene therapy (60) cellular therapy (17) contract development (10) cell and gene therapy (9) cobra biologics (4) cognate bioservices (4) vigene biosciences (4)
In June 2021, Charles River acquired Vigene Biosciences, a trusted leader in contract development and manufacturing solutions for gene therapy. The rebranding is now complete. Vigene’s website has been completely integrated into Charles River’s website.
Leverage our innovative viral vector and plasmid products to enhance and accelerate your gene discovery research and programs. Browse Now
Still have questions for our viral vector and plasmid specialists? Ask an Expert
(주)킴앤프렌즈